Protagonist Therapeutics, Inc Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Protagonist Therapeutics, Inc (PTGX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $10.51 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-25
- Protagonist Therapeutics, Inc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- Protagonist Therapeutics, Inc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- Protagonist Therapeutics, Inc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- Protagonist Therapeutics, Inc right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $10.51M.
- Protagonist Therapeutics, Inc right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $1.37M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $10.51M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.51M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $10.51M 10-Q · filed 2025-08-06 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.37M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $1.37M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |